neuromuscular disorders guillain-barré syndrome - chapter 30 myasthenia gravis – chapter 31

51
Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Post on 19-Dec-2015

218 views

Category:

Documents


2 download

TRANSCRIPT

Page 1: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Neuromuscular Disorders

Guillain-Barré Syndrome - Chapter 30

Myasthenia Gravis – Chapter 31

Page 2: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Neuromuscular Diseases

• Guillain-Barré Syndrome

• Myasthenia Gravis

• Amyotrophic Lateral Sclerosis (ALS)

• Muscular Dystrophy

• Multiple Sclerosis

• Cerebral Palsy

• Spinal cord injury

Page 3: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Guillain-Barré Syndrome

Page 4: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Definition• An acute, usually rapidly progressive form of

inflammatory polyneuropathy characterized by muscular weakness and mild distal sensory loss, which in about 2/3 of cases, begins 5 days to 3 weeks after a banal infectious disorder, surgery, or an immunization.• Disorder of the peripheral nervous system.

• Also known as• Landry's Ascending Paralysis• Acute Inflammatory Demyelinating

Polyradiculoneuropathy• Post-infectious polyneuritis• Acute post-infection polyneuropathy

Page 5: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Etiology

• Cause is unknown.• Autoimmune?

• Follows a febrile infection by 1-4 weeks: • Upper Respiratory Tract• GI illness• Viruses and bacteria

• Infectious mononucleosis is associated with 25% of cases.

• Followed the swine flu influenza vaccination in 1976.• 500 cases of Guillain-Barré and 25 deaths.

Page 6: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Etiology

• Parainfluenza 2

• Variola

• Measles

• Mumps

• Hepatitis A and B

• Mycoplasma Pneumoniae

• Salmonella typhi

Page 7: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Etiology

• All age groups• Greater incidence in age group > 45 years

age.

• Either sex• Greater incidence in males.

• Greater incident in white population.

• No seasonal clustering.

Page 8: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Pathophysiology

• Most common acquired demyelinating neuropathy.

• Inflammation and deterioration of peripheral nervous system.• Decreased ability of the neurons to transmit

impulses to the muscles.• Paralysis.

Page 9: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31
Page 10: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31
Page 11: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31
Page 12: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Neurilemma

• The outer membrane of the Schwann cells is called the neurilemma.

• Neurilemma is essential for regeneration of cut and injured axons.

• Axons in the brain and spinal cord have no neurilemma and therefore cannot regenerate.

Page 13: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Clinical Manifestations• Progressive ascending skeletal muscle paralysis.

• Ground to brain (G-B).

• Tingling sensation and numbness. • Paresthesia

• Loss of deep tendon reflexes.• Sensory nerve impairment.• Peripheral facial weakness.• Decreased gag reflex.• Decreased ability to swallow.

• Dysphagia

Page 14: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Symptoms

• Fever

• Malaise

• Nausea prostration.

• Tingling or numbness in extremities.• Feet/legs affected first.

• Paralysis and loss of reflexes.

Page 15: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Ventilatory Failure

• Mucous Accumulation

• Airway Obstruction

• Alveolar Consolidation

• Atelectasis

Page 16: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Progression of the Disease

• Paralysis peaks in less than 10 days.

• Progression of the paralysis may stop at any point.

• As paralysis reaches its maximum, it usually remains unchanged for a few days to weeks.

Page 17: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Clinical Manifestations

• ABG• Acute ventilatory failure with hypoxemia.

• Cyanosis

• PFT• Restrictive lung disease.• Decreased volumes.

• Breath Sounds decreased.

Page 18: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Diagnosis

• Neurological symptoms.

• Cerebral Spinal Fluid.• Increased protein and normal cell count.

• Electro-diagnostic studies.

Page 19: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

X-ray

• Normal.

• If atelectasis is present:• Radiopaque or radiodense (white).

Page 20: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Autonomic Nervous System Dysfunction

• Develops in 50% of cases• Sympathetic

• Parasympathetic• Loss of bowel and bladder sphincter control may

occur

Page 21: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Management

• Oxygen

• Frequent monitoring of pulmonary function parameters.• Vital capacity• NIF or MIP & MEP

• Frequent monitoring of PO and ABG.

• Mechanical ventilation:• Ventilatory Respiratory Failure.• Tracheostomy

Page 22: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Management

• Hyperinflation Protocol.

• Bronchial Hygiene Protocol.

• Risk of thromboembolic events:• Subcutaneous heparin.• Elastic stockings.• Passive range of motion exercises.

• Management of bedsores:• Frequent turning.

• Monitor for Pneumonia (infection).

Page 23: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Management

• Urinary catheterization.• Treat cardiac dysrhythmias.• Plasmapheresis

• Withdraw blood.• Separate out the plasma & discard.• Re-infuse the cells with fresh frozen plasma.• Decreases the antibodies. • Total of five exchanges of 3 L each over 8-10

days.

• Steroid Therapy is controversial.

Page 24: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Pulmonary Function Monitoring

• Mechanical Ventilation is indicated if:• If VC decreases to 10 - 15 cc/kg or less.• NIF (MIP) is –20 cm H20 or lower.• f increases above 30/min.

Page 25: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Prognosis

• Spontaneous recovery is expected in 85-95% of cases.

• Improvement may take weeks or months.

• 30% of adults have residual weakness at 3 years.

Page 26: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Myasthenia Gravis

Page 27: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Definition

• A disease characterized by episodic muscle weakness caused by loss or dysfunction of acetylcholine receptors.• Chronic disorder. • Axon and receptor site of the voluntary

muscle.• Periods of fatigue with improvement following

rest.

Page 28: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Etiology

• Circulating anti-ACh receptor antibodies disrupt the chemical transmission of ACh.• Blocking the ACh from the receptor site.• Accelerating the breakdown of ACh.• Destroying the receptor sites.

• Thymus gland is abnormal:• Antibodies thought to come from the thymus

gland.

Page 29: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Etiology• Twice as common in women.• Peak age of onset for females is 15 to 35 years.• Peak age of onset for males is 40 to 70 yrs.• Signs/symptoms are provoked by:

• Emotional upset.• Physical stress.• Exposure to extreme temperature changes.• Febrile illness.• Pregnancy.

• Death is possible but incidence of deaths decline after 10 years.

Page 30: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Anatomic Alterations

• Isolated groups of muscles (eyelids).

• Generalized muscle weakness:• May include the diaphragm.• Ventilatory Failure.

Page 31: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31
Page 32: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Clinical Findings

• Weakness of striated muscle• Eye muscles (ptosis).• Extraocular muscles (diplopia).• Muscles of the lower portion of the face

(speech impairment).• Chewing and swallowing muscles (dysphagia).• Muscles of the arms and legs.

Page 33: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Clinical Findings

• Descending paralysis.• Mind to Ground (MG)

• Gradual onset.

• First symptoms.• Drooping of the eyelids.

• If only the eyes are involved than it is referred to as Ocular Myasthenia.

Page 34: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Clinical Findings

• Generalized skeletal muscle disorder• Muscles of neck and face.• Unable to chew and swallow.

• Aspiration

• Unable to speak clearly. • Weakness of neck muscles causes the

patients head to fall forward.

Page 35: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Clinical Findings

• Weakness of arms and legs results in difficulty in:• Climbing stairs.• Lifting objects.• Maintaining balance.• Walking.• Hand cannot lift to the mouth.

Page 36: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Clinical Findings

• Pain is rare.

• Tendon reflexes remain intact.

• Patient may demonstrate normal health for weeks and months at a time.

• May only show signs of weakness late in the day or at night (exhaustion).

• Develop a sudden and transient generalized muscle weakness that includes the diaphragm.

Page 37: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Clinical Findings

• If ventilatory failure is handled properly the chest x-ray findings should be normal.

• If improperly managed:• Alveolar consolidation• Atelectasis• Excessive secretions

Page 38: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

ABG

• Acute ventilatory failure with hypoxemia• Decreased pH

• Increased PaCO2,

• Decreased PaO2

• Hypoxemia secondary to hypoventilation

Page 39: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Clinical Findings

• Pulmonary Functions• Decreased volumes.

• Cyanosis

• Diminished BS

• X-ray• Normal or radiopaque (white) if atelectasis is

present.

Page 40: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Diagnosis

• Clinical history.

• Clinical response to an IV injection of edrophonium chloride (Tensilon).• Tensilon Test• Tensilon is an anticholinesterase.

• Electrophysiological tests (EMG).

• Circulating antibody levels in the blood.

• Enlarged Thymus gland.

Page 41: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Thymus Gland

• Manufacture T-lymphocytes.

Page 42: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Management

• Patients may live a normal life span.

• Exacerbation:• Oxygen• Frequent monitoring of VC and NIF.

• Frequent monitoring of BP and SpO2.

• Frequent monitoring of ABG.• Mechanical ventilation.

Page 43: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Management of MG

• Anticholinesterase Drugs• Edrophonium Chloride (Tensilon)• Neostigmine (Prostigmine)• Pyridostigmine (Mestinon)

• Steroid Therapy• Prednisone

• ACTH therapy

Page 44: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Management of MG

• Thymectomy• Useful in young adult females

• Plasmapheresis

• Bronchial hygiene

• Hyperinflation protocol • Atelectasis

Page 45: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Myasthenia Crisis vs.Cholinergic Crisis

• Myasthenia Crisis• Exacerbation of the disease.• Muscle strength improves after Tensilon Test.• Increase dosage of anticholinesterase agents.

• Cholinergic Crisis• Too much anticholinesterase drugs.• No muscle strength noted after Tensilon.• Stop or decrease dosage of anticholinesterase

agents and give atropine.• MEDICAL EMERGENCY

Page 46: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

SPINAL CORD INJURY

Page 47: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Spinal Nerves

• 31 Pair• 8 Cervical• 12 Thoracic• 5 Lumbar• 5 Sacrospinal• 1 Coccygeal

Page 48: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Spinal Cord Injury

• High neck fractures (above C3).• Apnea.• All respiratory muscles are affected.• Mechanical ventilation/Tracheostomy.

• Injury to C3-C8 is a quadriplegic but retains some use of respiratory muscles.• Night-time mechanical ventilation.

• Injury below C8. • Cough weak and ineffective secretion

removal .• Loss of function of abdominal muscles.

Page 49: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Amyotrophic Lateral Sclerosis

Page 50: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

Lou Gehrig’s Disease• Anterior Horn Cells.• Weakness of hands and less often in the feet.• The site of onset is random, and progression is

asymmetric.• Dysarthria and dysphagia are due to involvement

of brain stem nuclei and pathways. • Sensory systems, voluntary eye movements, and

urinary sphincters are spared. • Rarely, a patient survives 30 years

• 50% die within 3 years of onset.• 20% live 5 years.• 10% live 10 years.

Page 51: Neuromuscular Disorders Guillain-Barré Syndrome - Chapter 30 Myasthenia Gravis – Chapter 31

• ALS can strike anyone.• Male or female• Any ethnic origin• At any age• Some have been diagnosed as teens• Usual onset is in middle age

• http://www.alsa.org/